The European Patent Office intends to grant Idogen’s patent application
Idogen AB (”Idogen”) today announces that the European Patent Office (”EPO”) has issued a “Notice of Intention to Grant”, which means that the patent office intends to grant Idogen’s patent application, covering the company’s tolerogenic vaccine technology. A related patent application received a Notice of Allowance in Japan in December 2016. The patent, and its validation in key European countries, will provide Idogen’s tolerogenic vaccine technology with broad protection and further strengthens the company’s patent portfolio.The European Patent Office has communicated its intention to